• Users Online: 175
  • Print this page
  • Email this page
Year : 2021  |  Volume : 12  |  Issue : 3  |  Page : 175-178

Clinical efficacy and safety of combined house dust mite subcutaneous immunotherapy and omalizumab in five cases of allergic rhinitis and asthma

1 Department of Allergy/ Asthma BLK Hospital and Director at National Allergy Center, New Delhi, India
2 National Allergy Centre, New Delhi and BLK Superspeciality Hopital, New Delhi, India

Correspondence Address:
Dr. P C Kathuria
1/3 East Patel Nagar, New Delhi - 110 008
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/injms.injms_7_21

Rights and Permissions

Allergen immunotherapy (AIT) is a well-recognized treatment for altering the natural course of respiratory allergy which builds immune tolerance and prevents progression of allergic diseases. In our five cases of house dust mite (HDM)-driven allergic rhinitis and asthma, combined HDM Subcutaneous Immunotherapy (HDM-SCIT) for 2 years with omalizumab for more than 12 months has achieved disease remission in four cases and disease control in one case along with long-term effect for 3 years after discontinuation of AIT. We hypothesize that combining HDM-SCIT and omalizumab is a promising strategy as it is effective, safe, and synergistic having immune-modifying activity in cases of HDM-driven Allergic Rhinitis and Asthma.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded23    
    Comments [Add]    

Recommend this journal